The store will not work correctly when cookies are disabled.
N-nonyl-1,3-diphenyl-1H-pyrazol-5-amine
ID: ALA3976360
PubChem CID: 117649186
Max Phase: Preclinical
Molecular Formula: C24H31N3
Molecular Weight: 361.53
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: CCCCCCCCCNc1cc(-c2ccccc2)nn1-c1ccccc1
Standard InChI: InChI=1S/C24H31N3/c1-2-3-4-5-6-7-14-19-25-24-20-23(21-15-10-8-11-16-21)26-27(24)22-17-12-9-13-18-22/h8-13,15-18,20,25H,2-7,14,19H2,1H3
Standard InChI Key: VZNUUKKRUURWGP-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 29 0 0 0 0 0 0 0 0999 V2000
3.2937 -16.4020 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.9751 -16.8634 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.6247 -16.3578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3408 -15.5832 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5210 -15.6142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0024 -17.6816 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3029 -18.1131 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3298 -18.9332 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0555 -19.3229 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7555 -18.8823 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7252 -18.0637 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.0182 -14.9695 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3259 -14.2071 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8194 -13.5595 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0051 -13.6771 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6999 -14.4438 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.2083 -15.0841 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.4139 -16.5845 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.0028 -16.0137 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7920 -16.2445 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3850 -15.6737 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.1743 -15.9004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7672 -15.3337 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5565 -15.5604 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1453 -14.9896 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.9346 -15.2204 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5276 -14.6496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 2 0
4 5 1 0
5 1 2 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
11 6 1 0
2 6 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 12 1 0
5 12 1 0
3 18 1 0
18 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
25 26 1 0
26 27 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 361.53 | Molecular Weight (Monoisotopic): 361.2518 | AlogP: 6.70 | #Rotatable Bonds: 11 |
Polar Surface Area: 29.85 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: ┄ | CX Basic pKa: 2.93 | CX LogP: 7.20 | CX LogD: 7.20 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.38 | Np Likeness Score: -1.15 |
References
1. (2014) Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases, |